Literature DB >> 22228035

3D-QSAR and molecular docking analysis of biphenyl amide derivatives as p38α mitogen-activated protein kinase inhibitors.

Pravin Sundarao Ambure1, Rahul Prakashchand Gangwal, Abhay T Sangamwar.   

Abstract

The p38α mitogen-activated protein (MAP) kinase plays a vital role in treating many inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease and psoriasis. Herein, we have performed 3D-QSAR and molecular docking analysis on a novel series of biphenyl amides to design potent p38 MAP kinase inhibitors. This study correlates the p38 MAP kinase inhibitory activities of 80 biphenyl amide derivatives to several stereochemical parameters representing steric, electrostatic, hydrophobic, hydrogen bond donor and acceptor fields. The resulting model from CoMFA and CoMSIA exhibited excellent [Formula: see text] values of 0.979 and 0.942, and [Formula: see text] values of 0.766 and 0.748, respectively. CoMFA predicted [Formula: see text] of 0.987 and CoMSIA predicted [Formula: see text] of 0.761 showed that the predicted values were in good agreement with experimental values. Glide (5.5) program gave the path for binding mode exploration between the inhibitors and p38α MAP kinase. We have accordingly designed novel p38α MAP kinase inhibitors by utilizing LeapFrog and predicted with excellent activity in the developed models.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228035     DOI: 10.1007/s11030-011-9353-y

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  22 in total

Review 1.  p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.

Authors:  J L Adams; A M Badger; S Kumar; J C Lee
Journal:  Prog Med Chem       Date:  2001

Review 2.  The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.

Authors:  G Camussi; E Lupia
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

3.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.

Authors:  A M Badger; J N Bradbeer; B Votta; J C Lee; J L Adams; D E Griswold
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

Review 5.  Role of cytokines in rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 6.  Cytokines in autoimmunity.

Authors:  F M Brennan; M Feldmann
Journal:  Curr Opin Immunol       Date:  1996-12       Impact factor: 7.486

7.  Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

Authors:  N J Liverton; J W Butcher; C F Claiborne; D A Claremon; B E Libby; K T Nguyen; S M Pitzenberger; H G Selnick; G R Smith; A Tebben; J P Vacca; S L Varga; L Agarwal; K Dancheck; A J Forsyth; D S Fletcher; B Frantz; W A Hanlon; C F Harper; S J Hofsess; M Kostura; J Lin; S Luell; E A O'Neill; S J O'Keefe
Journal:  J Med Chem       Date:  1999-06-17       Impact factor: 7.446

8.  Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.

Authors:  Richard M Angell; Tony D Angell; Paul Bamborough; David Brown; Murray Brown; Jacky B Buckton; Stuart G Cockerill; Chris D Edwards; Katherine L Jones; Tim Longstaff; Penny A Smee; Kathryn J Smith; Don O Somers; Ann L Walker; Malcolm Willson
Journal:  Bioorg Med Chem Lett       Date:  2007-10-17       Impact factor: 2.823

9.  Potential of p38 inhibitors in the treatment of rheumatoid arthritis.

Authors:  M L Foster; F Halley; J E Souness
Journal:  Drug News Perspect       Date:  2000-10

10.  Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.

Authors:  Richard Angell; Nicola M Aston; Paul Bamborough; Jacky B Buckton; Stuart Cockerill; Suzanne J deBoeck; Chris D Edwards; Duncan S Holmes; Katherine L Jones; Dramane I Laine; Shila Patel; Penny A Smee; Kathryn J Smith; Don O Somers; Ann L Walker
Journal:  Bioorg Med Chem Lett       Date:  2008-06-18       Impact factor: 2.823

View more
  5 in total

1.  Identification of dual Acetyl-CoA carboxylases 1 and 2 inhibitors by pharmacophore based virtual screening and molecular docking approach.

Authors:  Anuseema Bhadauriya; Gaurao V Dhoke; Rahul P Gangwal; Mangesh V Damre; Abhay T Sangamwar
Journal:  Mol Divers       Date:  2013-01-19       Impact factor: 2.943

2.  New molecular insights into the tyrosyl-tRNA synthase inhibitors: CoMFA, CoMSIA analyses and molecular docking studies.

Authors:  Shengrong Li; Jilin Fan; Chengkang Peng; Yiqun Chang; Lianxia Guo; Jinsong Hou; Miaoqi Huang; Biyuan Wu; Junxia Zheng; Longxin Lin; Gaokeng Xiao; Weimin Chen; Guochao Liao; Jialiang Guo; Pinghua Sun
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

3.  Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.

Authors:  Junxia Zheng; Hao Kong; James M Wilson; Jialiang Guo; Yiqun Chang; Mengjia Yang; Gaokeng Xiao; Pinghua Sun
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

4.  Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.

Authors:  Yaning Jian; Yuyu He; Jingjing Yang; Wei Han; Xifeng Zhai; Ye Zhao; Yang Li
Journal:  Int J Mol Sci       Date:  2018-02-23       Impact factor: 5.923

5.  Prediction and evaluation of the lipase inhibitory activities of tea polyphenols with 3D-QSAR models.

Authors:  Yi-Fang Li; Yi-Qun Chang; Jie Deng; Wei-Xi Li; Jie Jian; Jia-Suo Gao; Xin Wan; Hao Gao; Hiroshi Kurihara; Ping-Hua Sun; Rong-Rong He
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.